Cargando…

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

INTRODUCTION: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless...

Descripción completa

Detalles Bibliográficos
Autores principales: Majem, Margarita, Álvarez, Rosa, Ortega, Ana Laura, Ruiz de Alda, Lucía, Gordo, Rocío, García, J Francisco, Ivanova-Markova, Yoana, González-Domínguez, Almudena, San Cristóbal, Raquel Sánchez, Rojo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793412/
https://www.ncbi.nlm.nih.gov/pubmed/36628311
http://dx.doi.org/10.33393/grhta.2022.2449